Compounded Tirzepatide vs. Zepbound: What You Need to Know

*This article is for informational and educational purposes only. It is not medical advice. Compounded tirzepatide is not FDA-approved. Clinical research cited here was conducted using FDA-approved tirzepatide formulations. Individual results vary. Consult your licensed healthcare provider before starting, stopping, or adjusting any medication.*

---

If you're researching tirzepatide for weight loss, you've likely encountered two versions: Zepbound, the FDA-approved branded medication from Eli Lilly, and compounded tirzepatide, available through telehealth providers and compounding pharmacies at a substantially lower cost. Understanding what makes them different, and why both options exist, helps you have a more informed conversation with your healthcare provider.

This guide covers the regulatory status of each, the evidence behind tirzepatide as a weight loss treatment, how pricing and access differ, and what to look for if you're considering either option.

---

What Is Zepbound?

Zepbound is the brand name for tirzepatide approved by the FDA for chronic weight management in adults. The FDA approved Zepbound in November 2023 for use in adults with obesity (BMI 30 or higher) or adults with a BMI of 27 or higher who also have at least one weight-related health condition such as high blood pressure, type 2 diabetes, or high cholesterol.

Zepbound is manufactured by Eli Lilly and Company, the pharmaceutical company that also produces Mounjaro (tirzepatide for type 2 diabetes). It is a once-weekly injectable medication available in six dosing strengths, ranging from 2.5 mg to 15 mg.

As an FDA-approved medication, Zepbound has undergone rigorous review of its safety, efficacy, and manufacturing standards. It is covered by some commercial insurance plans, though coverage varies widely.

---

What Is Compounded Tirzepatide?

Compounded tirzepatide is prepared by licensed compounding pharmacies under patient-specific prescriptions. It uses tirzepatide as the active pharmaceutical ingredient, prepared in formulations that are not commercially available from a drug manufacturer.

Important regulatory distinction: Compounded tirzepatide is NOT FDA-approved. Compounding pharmacies prepare medications for individual patients based on prescriptions from licensed healthcare providers, but the compounded product itself has not gone through FDA review for safety, efficacy, or manufacturing consistency.

The term "compounded" does not mean "generic." A generic drug is an FDA-approved product bioequivalent to a reference branded drug. Compounded tirzepatide is a patient-specific preparation made by a pharmacy, not a manufacturer, and is not subject to the same approval process.

Compounded tirzepatide is typically available through telehealth providers that partner with 503A compounding pharmacies. 503A pharmacies are licensed by state boards and must comply with state pharmacy law and, for some interstate dispensing, federal guidelines. They operate under different regulatory requirements than manufacturers of FDA-approved drugs.

---

The Core Differences at a Glance

---

What the Research Shows About Tirzepatide

The clinical evidence base for tirzepatide's effectiveness in weight management comes from the SURMOUNT trial program, conducted using the FDA-approved branded formulation. The most important findings are relevant to understanding what tirzepatide can do as a treatment class.

The SURMOUNT-1 trial, published in *The New England Journal of Medicine* in 2022, enrolled 2,539 adults with obesity or overweight with weight-related health conditions (excluding type 2 diabetes) and found that tirzepatide 15 mg produced a mean body weight reduction of 20.9% over 72 weeks, compared to 3.1% in the placebo group [1]. This represents the largest weight reduction documented in a large-scale obesity medication trial to date.

The SURMOUNT-2 trial, published in *The Lancet* in 2023, enrolled adults with type 2 diabetes and obesity and documented mean weight reductions of 14.7% to 15.7% at the highest doses over 72 weeks, along with meaningful improvements in glycemic control [2].

These results were generated using Zepbound (or its diabetes-approved counterpart Mounjaro), not compounded tirzepatide. Because compounded formulations have not been studied in clinical trials, it is not appropriate to apply these efficacy figures directly to compounded versions. What the research establishes is that tirzepatide as an active ingredient has a well-characterized weight loss mechanism and a strong evidence base from large, rigorous trials.

For comparison, semaglutide, the active ingredient in Ozempic and Wegovy, produced a mean body weight reduction of 14.9% in the STEP 1 landmark trial [3]. Tirzepatide's dual mechanism, activating both GLP-1 and GIP receptors, appears to produce greater weight loss on average, though individual response always varies.

---

Why Compounded Versions Exist

The cost of Zepbound is a significant barrier for many patients. At a list price exceeding $1,000 per month, and with inconsistent insurance coverage, branded tirzepatide is financially out of reach for a large portion of the people who could benefit from it.

Compounding pharmacies have historically produced medications that are not commercially available, discontinued, or needed in specific formulations for individual patients. When Zepbound was unavailable in specific doses or when broader demand outpaced supply, compounded tirzepatide became a pathway for patients to access this treatment class at a price that made treatment sustainable.

The FDA's position on compounding of tirzepatide has evolved. As of 2025, the FDA determined that Zepbound is no longer in shortage, which affects the legal framework for compounding. This regulatory situation continues to shift, and providers offering compounded tirzepatide operate within an evolving legal landscape. If you're considering a compounded tirzepatide program, confirm with your provider that they are current on the legal and regulatory status.

---

What 503A Compounding Pharmacies Are

503A pharmacies are licensed compounding pharmacies that prepare medications for individual patients based on valid prescriptions. They must comply with state pharmacy board standards and meet the requirements of the Federal Food, Drug, and Cosmetic Act for patient-specific compounding.

Quality practices at reputable 503A pharmacies include:

• Certificate of Analysis (COA) testing for each batch of active pharmaceutical ingredient
• Sterility testing for injectable preparations
• Potency verification
• Licensed pharmacist oversight

Not all compounding pharmacies meet the same standards. When evaluating a compounded tirzepatide program, asking about the specific pharmacy's testing and quality protocols is a reasonable and recommended step.

---

---

Access Pathway: How Each Version Is Prescribed

Both Zepbound and compounded tirzepatide require a prescription from a licensed healthcare provider. The access pathway looks different in practice.

For Zepbound:

• Prescription from a physician, NP, or PA (in person or via telehealth)
• Dispensed through retail or specialty pharmacy
• Insurance prior authorization may be required
• Manufacturer savings programs exist (Lilly's savings card can reduce cost for eligible patients)

For compounded tirzepatide:

• Prescription via telehealth intake and provider consultation
• Dispensed directly by compounding pharmacy to patient
• Cash pay (no insurance billing)
• Lower upfront cost, no prior authorization process

The telehealth pathway for compounded GLP-1 medications has made treatment accessible to patients who previously could not afford or navigate the insurance-based system. The trade-off is the absence of FDA approval for the compounded product and variable quality standards depending on the pharmacy used.

---

Safety Considerations for Both Options

The side effect profile of tirzepatide is consistent across the class, regardless of whether the formulation is branded or compounded. Common side effects include nausea, vomiting, diarrhea, constipation, and decreased appetite, particularly during dose titration. Most patients tolerate these effects well when doses are increased gradually.

The labeling for Zepbound includes a precautionary statement about medullary thyroid carcinoma (a rare cancer of specific thyroid cells) based on animal studies, and the medication is contraindicated in patients with a personal or family history of this condition or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). These precautions apply to the tirzepatide class as a whole.

A licensed provider should review your complete medical history and current medications before prescribing either version. For compounded tirzepatide, the prescribing provider also has a responsibility to ensure you understand the non-FDA-approved status of the medication.

---

Which Option Is Right for You?

This is a conversation to have with your healthcare provider, not a decision to make based on price alone. A few practical considerations:

Consider Zepbound if:

• You have insurance coverage that would meaningfully reduce the cost
• You have specific dosing needs that align with commercially available strengths
• Your provider has a strong preference for an FDA-approved product
• You have Medicare or a health plan with an established prior authorization pathway

Consider compounded tirzepatide if:

• The cost of Zepbound is prohibitive and uninsured
• You are working with a telehealth provider experienced in GLP-1 prescribing
• You have confirmed the compounding pharmacy's testing and quality standards
• You understand and accept the non-FDA-approved status of the compounded product

The most important factor is working with a licensed provider who can monitor your progress, manage side effects, and adjust your treatment plan as needed. GLP-1 therapy produces the best outcomes when it is part of a supervised program that also addresses diet, physical activity, and long-term weight maintenance.

---

*Ready to explore your options? [Check your eligibility](/assessment) to see if a medically supervised compounded GLP-1 program may be right for you.*

---

*Compounded tirzepatide is not FDA-approved and is not the same as Zepbound. Clinical trial data cited in this article was generated using FDA-approved branded formulations; results may differ from compounded versions. This content is educational and does not constitute medical advice. Results vary by individual. Always consult a licensed healthcare provider before making changes to your treatment.*

---

References

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. *N Engl J Med*. 2022;387(3):205-216. [PMID: 35658024](https://pubmed.ncbi.nlm.nih.gov/35658024/)

1. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). *Lancet*. 2023;402(10402):613-626. [PMID: 37385275](https://pubmed.ncbi.nlm.nih.gov/37385275/)

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. *N Engl J Med*. 2021;384(11):989-1002. [PMID: 33567185](https://pubmed.ncbi.nlm.nih.gov/33567185/)